Understanding how B cells affect lung cancer treatment response
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
This study is looking at how certain immune cells in your body respond to new cancer treatments for lung cancer, and by joining, you can help researchers find ways to make these treatments work better for you and others.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10998089 on NIH RePORTER |
What this research studies
This research investigates the role of B lineage cells in the response of patients with resectable non-small cell lung cancer (NSCLC) to neoadjuvant immune-based therapies. By analyzing blood and tissue samples from patients, the study aims to identify mechanisms that influence treatment effectiveness and resistance. The goal is to develop better treatment strategies that enhance the benefits of immune checkpoint inhibitors and prevent therapeutic resistance. Patients participating in this research may contribute to a deeper understanding of how their immune system interacts with cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with resectable non-small cell lung cancer who are scheduled to receive neoadjuvant immune-based therapy.
Not a fit: Patients with non-resectable lung cancer or those not receiving neoadjuvant therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for lung cancer patients, enhancing their chances of responding to therapies.
How similar studies have performed: Previous studies have shown promising results in understanding immune responses in lung cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Cascone, Tina — University of Tx Md Anderson Can Ctr
- Study coordinator: Cascone, Tina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.